AlphaCentric Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

AlphaCentric Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$673K	Buy	3,561 +193	+6%	+$33.7K	0.67%	38
2025 Q4	$573K	Buy	+3,368	New	+$516K	0.57%	55
2024 Q4	–	Sell	-15,500	Closed	-$1.73M	–	251
2024 Q3	$1.73M	Buy	15,500 +4,500	+41%	+$493K	1.28%	24
2024 Q2	$1.17M	Buy	11,000 +2,500	+29%	+$275K	0.86%	40
2024 Q1	$1.02M	Sell	8,500 -2,000	-19%	-$245K	0.62%	61
2023 Q4	$1.29M	Sell	10,500 -16,000	-60%	-$2M	0.87%	43
2023 Q3	$3.43M	Sell	26,500 -14,250	-35%	-$1.9M	1.95%	7
2023 Q2	$5.05M	Buy	40,750 +33,750	+482%	+$4.54M	2.8%	1
2023 Q1	$1.02M	Buy	7,000 +3,500	+100%	+$518K	0.71%	49
2022 Q4	$558K	Hold	3,500	–	–	0.55%	66
2022 Q3	$467K	Buy	+3,500	New	+$532K	0.48%	61
2021 Q4	$1.27M	Buy	+10,000	New	+$1.31M	0.37%	19
2020 Q4	–	Sell	-350	Closed	-$50K	–	219
2020 Q3	$50K	Sell	350 -275	-44%	-$34.1K	0.02%	107
2020 Q2	$69K	Buy	+625	New	+$69.1K	0.04%	70

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

AlphaCentric Advisors's JAZZ Position: Q1 2026 in Review

AlphaCentric Advisors increased its Jazz Pharmaceuticals (JAZZ) stake by 5.7% in Q1 2026, buying an estimated $33.7K and bringing the position to 3,561 shares worth $673K. The position accounts for 0.67% of the portfolio, ranked #38.

AlphaCentric Advisors first reported a position in JAZZ in Q2 2020 and has held it in 14 quarters since. The position peaked at $5.05M in Q2 2023. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

AlphaCentric Advisors held 3,561 shares of Jazz Pharmaceuticals worth $673K as of Q1 2026.
AlphaCentric Advisors bought 193 Jazz Pharmaceuticals shares in Q1 2026, an estimated $33.7K.
Jazz Pharmaceuticals made up 0.67% of AlphaCentric Advisors's portfolio in Q1 2026, its #38 holding.
AlphaCentric Advisors first reported a position in Jazz Pharmaceuticals in Q2 2020 and has held it in 14 quarters since.
AlphaCentric Advisors's Jazz Pharmaceuticals position peaked at $5.05M in Q2 2023.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.